Skip to content
DataLookout
Menu

MONITORNCT06761482

Non-Invasive Monitoring of Pediatric Kidney Transplant Recipients and Immunosuppression Personalization

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved at least 10 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Mar 1, 2027 to Jan 22, 2028 Show 4 more changesShow less
    • Recruitment opened
    • Study completion moved earlier from Mar 1, 2029 to Jan 22, 2029
    • Enrollment target: 160 to 170
    • Study title shortened, about 6 words
  2. Notable Trial status: Not Yet Recruiting to Recruiting Show 7 more changesShow less
    • Primary completion date: Mar 1, 2027 to Jan 22, 2028
    • Start date changed from estimate of Mar 1, 2025 to Jan 22, 2026
    • Eligibility criteria expanded, about 8 words
    • Study completion date: Mar 1, 2029 to Jan 22, 2029
    • Secondary endpoints: details revised at 1 of 5 entries
    • Site details revised
    • Study description expanded, about 2 words
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Number of kidney allograft during the 2 years post-transplantation
Timeframe: 24 months
Exposure to calcineurin inhibitors (mean tacrolimus level) between month 6 and month 24 post-transplantation.
Timeframe: 24 months

Secondary (5)

Number of participants with adverse events as assessed by CTCAE v4.0 in each group
Cost-utility
Allograft fibrosis on the surveillance biopsy at 24 months
Allograft function (estimated Glomerular Filtration Rate) at 24 months
Predicted allograft survival until 10 years after evaluation

Arms and interventions

monitoring by dd-cfDNAExperimental
monitoring by T-VisExperimental
monitoring by dd-cfDNA and T-VisExperimental
Current standard of care based on surveillance biopsies and biological monitoringNo intervention

Procedures: monitoring by dd-cfDNA, monitoring by T-Vis, monitoring by dd-cfDNA+ T-Vis

Sites

1 site in 1 country

  • Robert Debré HospitalParis, France